Viatris IncVTRS
時価総額
$122.8億
PER
処方薬とジェネリックを扱う医薬品の最大手。循環器から腫瘍まで複雑薬を含むポートフォリオを展開。2024年に第III相資産を350百万ドルで取得、FDAのインド工場警告が影響。米国・欧州・新興市場で展開。
| 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net sales | 11,946 | 17,886 | 16,263 | 15,427 | 14,739 |
| Other revenues | - | - | - | - | 47 |
| Cost of sales | 8,149 | 12,311 | 9,766 | 8,988 | 9,116 |
| Gross profit | 3,797 | 5,576 | 6,497 | 6,439 | 5,624 |
| Research and development | - | - | 662 | 805 | 809 |
| Acquired IPR&D | - | - | - | 106 | 28 |
| Selling, general and administrative | 3,345 | 4,529 | 4,179 | 4,650 | 4,426 |
| Litigation settlements and other contingencies, net | -108 | -329 | -4 | -112 | -351 |
| Total operating expenses | 4,008 | 5,610 | 4,882 | 5,672 | 5,614 |
| Earnings (loss) from operations | -211 | -34 | 1,615 | 766 | 10 |
| Interest expense | 498 | 636 | 592 | 573 | 550 |
| Other expense (income), net | -13 | 6 | 1,791 | 10 | -83 |
| Earnings (loss) before income taxes | -721 | -664 | 2,813 | 203 | -623 |
| Income tax provision | -51 | 605 | 735 | 148 | 11 |
| Net (loss) earnings | -670 | -1,269 | 2,079 | 55 | -634 |
| Basic (in USD per share) | -1.11 | -1.05 | 1.71 | 0.05 | -0.53 |
| Diluted (in USD per share) | -1.11 | -1.05 | 1.71 | 0.05 | -0.53 |